Comparative analysis of losatan and enalapril antihypertensive efficacy (ELLA trial)
##semicolon##
arterial hypertension##common.commaListSeparator## losartan##common.commaListSeparator## enalapril##common.commaListSeparator## microalbuminuria##article.abstract##
Aim. To compare antihypertensive efficacy of АТ1 receptors blocker (losartan) and ACE inhibitor (enalapril), including their combinations with hydrochlorothiazide.
Material and methods. 60 patients (30-65 y.o.) with arterial hypertension (HT) of stages 1-3 were involved in 12-week opened comparative randomized study. Patients of group-I (n=30) received losartan, patients of group-II (n=30) - enalapril. Blood pressure (BP) changes assessed on the basis of clinical measurements and ambulatory monitoring. Microalbuminuria (MAU) levels, plasma aldosterone levels and plasma renin activity were estimated.
Results. Target BP levels were reached in 76,6% of patients in group-I and in 73,3% of patients in group-II. Among patients with moderate HT of stage 2 (n=50) target BP levels were reached in 96% of patients in group-I and in 72% of patients in group-II. Patients of both groups had positive changes in BP levels according to ambulato-ry BP monitoring. Significant reduction in MAU level and uric acid plasma concentrations were observed.
Conclusion. Losartan (Losap, Zentiva) and losartan combination with hydrochlorothiazide (Losap-plus, Zentiva) demonstrated antihypertensive efficacy comparable with this of enalapril as well as nephroprotective features.
##submission.citations##
Verdecchia P, Reboldi G, Angeli F et al. Angiotenzin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46(2):386-92.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25(5):951-8.
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359(9311): 995-1003.
Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on the left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20(9): 1855-64.
Чихладзе Н.М., Белоусов Ю.Б., Егорова Н.А. и др. Исследование эффективности применения лозартана у больных артериальной гипертонией. Кардиоваск тер профилакт 2007;(2):5-11.
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-87.
Uribe Flores JD, Hernandes Jacome M, Guevara Donde J, Segura X. Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hypertension. Arch Cardiol Mex 2004; 74(3):192-9
De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 2002; 16(2):133-40.
Papademetriou V, Devereux RB, Narayan P, et al. Similar effects of isolated systolic hypertension on left ventricular geometry and function: the LIFE study. Am J Hypertens 2001; 14(8 Pt 1):768-74
Soffer BA, Wright JT, Pratt H et al. Effects of losartan on a background of hydrochlortiazide in patients with hypertension. Hypertension 1995; 26: 112-7
Würzner G, Gerster JC, Chiolero A et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2001; 19(10): 1855-60
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimumo GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93(6): 817-21.
Fang J, Alderman MH. Serum uris acid and cardiovascular mortality. The NHANES I epidemiologic followup study, 1971-1992. JAMA 2000; 283(18): 2404-10
Laverman GD, Andersen S, Rossing P. et al. Renoprotection with and without blood pressure reduction. Kidney Int Suppl 2005; (94):S54-9
Andersen S, Tarnow L, Rossing P et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57(2): 601-6.
